ADVERTISEMENT

Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Ischemia Modified Albumin Levels in Patients with Insulin Resistance

Rabia Seker,Elif Ayca Sahin,Aziz Sener.




Abstract

Objective
Insulin resistance (IR) is a crucial characteristic of type 2 diabetes mellitus (T2DM) and can also occur independently or in other conditions such as obesity and metabolic syndrome. Oxidative stress significantly contributes to IR pathology. Ischemia-modified albumin (IMA) is a biomarker of oxidative stress and has been studied for its potential link to IR. This study aimed to identify the relationship between IMA levels and IR.
Materials and Methods
We conducted a prospective involving 101 IR patients without Diabetes Mellitus and 101 healthy controls. HOMA-IR was used to classify IR and control groups. IMA levels were measured using a colorimetric method. IMA values were compared between the groups and correlations between IMA and other parameters were evaluated.
Results
There was no statistically significant difference in IMA levels between the IR and control groups (p=0.27). Additionally, no significant correlation was observed between IMA and HOMA-IR (p=0.60). Significant differences were found in glucose, insulin, and HOMA-IR levels between the IR and control groups (p

Key words: Insulin resistance; oxidative stress; ischemia-modified albumin; type 2 diabetes mellitus; HOMA-IR.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Author Tools
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.